The earnings call reflects strong growth in prescription numbers and revenue, successful cost management, and a positive resolution regarding product exclusivity. However, there are potential challenges with supply disruptions and Medicare coverage. The strategic focus on gastroenterologists is expected to drive further growth.

Company Guidance

During the Phathom Pharmaceuticals Second Quarter 2025 earnings call, the company reported significant growth and provided positive guidance for the year. Key metrics included a 39% increase in Q2 revenues to $39.5 million compared to Q1, driven by a 36% growth in VOQUEZNA prescriptions, totaling approximately 173,000 in the quarter. The company anticipates full-year 2025 revenues between $165 million and $175 million, exceeding analyst estimates. Phathom also highlighted its cost-saving initiatives, achieving a $12 million reduction in non-GAAP operating expenses from Q1. The company ended Q2 with $150 million in cash, expecting to reach profitability by 2026. The sales strategy pivot to focus on gastroenterologists was emphasized, with these specialists contributing 70% of VOQUEZNA prescriptions. Furthermore, Phathom plans to start a Phase II trial for eosinophilic esophagitis in Q4, with the potential for a future six-month pediatric exclusivity extension.

Strong Prescription Growth

Over 580,000 VOQUEZNA prescriptions have been filled since launch, with a 49% growth in 14 weeks. In Q2, approximately 173,000 prescriptions were filled, marking a 36% growth over Q1.

Revenue and Cost Management

Reported $39.5 million in revenue for Q2, representing a 39% growth over Q1. Implemented cost savings initiatives mid-quarter, resulting in a $12 million reduction in Q2 non-GAAP OpEx compared to Q1.

Positive Exclusivity Resolution

Achieved a positive resolution to the citizens petition, securing exclusivity for VOQUEZNA tablets through May 2032, with potential extension to 2033.

Refocused Sales Strategy

Shifted sales focus to gastroenterologists, with 70% of prescriptions coming from GIs. This strategy is expected to drive deeper engagement and increase adoption.

Financial Stability

Ended the quarter with approximately $150 million in cash, with expectations to reach profitability by 2026 without additional equity financing.

Phathom Pharmaceuticals (PHAT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHAT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.47 / -	-1.32	―	―	―
Aug 07, 2025	2025 (Q2)	-0.95 / -1.05	-1.56	32.69% (+0.51)
May 01, 2025	2025 (Q1)	-1.10 / -1.31	-1.42	7.75% (+0.11)
Mar 06, 2025	2024 (Q4)	-1.22 / -1.05	-1.39	24.46% (+0.34)
Nov 07, 2024	2024 (Q3)	-1.47 / -1.32	-0.76	-73.68% (-0.56)
Aug 08, 2024	2024 (Q2)	-1.32 / -1.56	-0.84	-85.71% (-0.72)	―
May 09, 2024	2024 (Q1)	-1.32 / -1.42	-0.89	-59.55% (-0.53)	―
Mar 07, 2024	2023 (Q4)	-1.08 / -1.39	-1.33	-4.51% (-0.06)	―
Nov 09, 2023	2023 (Q3)	-0.89 / -0.76	-1.32	42.42% (+0.56)	―	―
Aug 10, 2023	2023 (Q2)	-0.98 / -0.84	-1.33	36.84% (+0.49)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHAT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$8.68	$9.40	+8.29%
May 01, 2025	$4.29	$3.36	-21.68%
Mar 06, 2025	$6.08	$5.90	-2.96%
Nov 07, 2024	$18.00	$18.50	+2.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Phathom Pharmaceuticals (PHAT) report earnings?

Phathom Pharmaceuticals (PHAT) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Phathom Pharmaceuticals (PHAT) earnings time?

Phathom Pharmaceuticals (PHAT) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHAT EPS forecast?

PHAT EPS forecast for the fiscal quarter 2025 (Q3) is -0.47.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing